GRIA2 is a useful marker for distinguishing SFT from most mimics. Among other CD34-positive tumours, GRIA2 is also expressed in DFSP; however, clinical and histological features aid in their distinction. GRIA2 shows a limited distribution in other soft tissue tumours.
No takes yet. Share an insight, caveat, or question.
Vivero et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: